- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Geron Corporation (GERN)
Geron Corporation stock price live, this page displays NASDAQ GERN stock exchange data. View the GERN premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Geron Corporation real time stock price chart below.
What Is the Geron Corporation Stock Price Today?
The Geron Corporation stock price today is 1.3400.
What Is the Stock Symbol for Geron Corporation?
The stock ticker symbol for Geron Corporation is GERN.
Is GERN the Same as $GERN?
$GERN is a common way to refer to the Geron Corporation ticker symbol in social media, forums, and online discussions. The dollar sign is a shorthand convention used to indicate that it is a stock ticker symbol
What Stock Exchange Does Geron Corporation Trade On?
Geron Corporation is listed and trades on the NASDAQ stock exchange.
Is Geron Corporation a Good Stock to Buy?
Determining whether Geron Corporation—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess the current Geron Corporation share price compared with the fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the GERN quote. (ISIN: US3741631036)
What Is the Geron Corporation Stock Price Today?
The Geron Corporation stock price today is 1.3400.
What Is the Stock Symbol for Geron Corporation?
The stock ticker symbol for Geron Corporation is GERN.
Is GERN the Same as $GERN?
$GERN is a common way to refer to the Geron Corporation ticker symbol in social media, forums, and online discussions. The dollar sign is a shorthand convention used to indicate that it is a stock ticker symbol
What Stock Exchange Does Geron Corporation Trade On?
Geron Corporation is listed and trades on the NASDAQ stock exchange.
Is Geron Corporation a Good Stock to Buy?
Determining whether Geron Corporation—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess the current Geron Corporation share price compared with the fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the GERN quote. (ISIN: US3741631036)
Currency in USD
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1.3100
1.3600
52 wk Range
1.0400
2.0100
Earnings results expected today
1/2
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1.31001.3600
52 wk Range
1.04002.0100
Key Statistics
Edit
Prev. Close
Open
Volume
Average Vol. (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Vol. (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
GERN Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Price Target
4.2500
Upside
+217.16%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Analysts do not anticipate the company will be profitable this year
Geron names Timothy Williams as chief legal officer- Investing.com
Form 4 Geron Corporation For: 1 July- Investing.com
- Form 4 Geron Corporation For: 1 July
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Strong Buy
Moving Averages
Sell
Analyst Ratings
4 Buy
1 Hold
0 Sell
Ratings:
5 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 4.2500
(+217.16% Upside)
Geron Corporation SWOT Analysis
Path to Profitability | Financial trajectory shows meaningful progress with projected EPS improving from negative $0.11 to negative $0.05, supported by favorable biotech sector dynamics |
Price Target Outlook | Analysts maintain Overweight rating with $4.00 price target, representing substantial upside from current levels despite near-term execution challenges |
Leadership Renewal | New CEO brings strategic reset potential, though tangible results from fresh management direction will require several months to materialize and execute |
Commercial Headwinds | Geron's flagship oncology therapeutic Rytelo faces revised sales expectations as market penetration proceeds slower than anticipated amid competitive pressures |
Geron Corporation Earnings Call Summary for Q1/2026
- Geron reported Q1 2026 revenue of $61.8M, up 31% YoY, driven by sole product Rytelo; EPS of -$0.01 beat forecast of -$0.02 by 50%.
- Operating expenses declined 9% YoY to $50.4M, demonstrating disciplined cost management; company maintains strong cash position of $341M.
- Stock rose 1.82% in premarket trading to $1.68; shares have delivered 53% return over past six months and 25% year-to-date.
- Company reaffirmed full-year 2026 revenue guidance of $220M-$240M, expecting stronger growth in second half with gross-to-net in low-mid 20% range.
- Management emphasized strategic investments in Rytelo and R&D diversification; analysts note company not expected to be profitable in 2026.
Last Updated: 05/06/2026, 08:47 AM
Read Full TranscriptEarnings
Latest Release
May 06, 2026
EPS / Forecast
-0.01 / -0.02
Revenue / Forecast
51.84M / 50.11M
Compare GERN to Peers and Sector
Metrics to compare | GERN | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipGERNPeersSector | |
|---|---|---|---|---|
P/E Ratio | −12.8x | −7.5x | −0.4x | |
PEG Ratio | −0.23 | −0.03 | 0.00 | |
Price / Book | 3.8x | 6.3x | 2.6x | |
Price / LTM Sales | 4.4x | 69.5x | 3.0x | |
Upside (Analyst Target) | 212.5% | 46.1% | 51.9% | |
Fair Value Upside | Unlock | 1.2% | 7.2% | Unlock |
Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. The company’s product pipeline includes RYTELO, a telomerase inhibitor for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia; IMerge which is in Phase 3 clinical trial for the treatment of lower-risk myelodysplastic syndromes; IMpactMF that is in Phase 3 for the treatment of relapsed/refractory myelofibrosis; Impress which is in Phase 2 clinical trial to treat higher risk myelodysplastic syndromes and acute myeloid leukemia (AML); IMproveMF which is in Phase 1 clinical trial for the treatment of frontline myelofibrosis; and IMAGINE which is in phase 1/2 clinical trial for the treatment of relapsed/refractory AML. Geron Corporation was incorporated in 1990 and is headquartered in Foster City, California.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Geron (GERN) Stock Price Today?
The Geron stock price today is 1.3400 USD.
What Stock Exchange Does Geron Trade On?
Geron is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Geron?
The stock symbol for Geron is "GERN."
What Is the Geron Market Cap?
As of today, Geron market cap is 859.6400M USD.
What Is Geron's Earnings Per Share (TTM)?
The Geron EPS (TTM) is -0.1008.
When Is the Next Geron Earnings Date?
Geron will release its next earnings report on Aug 05, 2026.
From a Technical Analysis Perspective, Is GERN a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has Geron Stock Split?
Geron has split 0 times.
How Many Employees Does Geron Have?
Geron has 258 employees.
What is the current trading status of Geron (GERN)?
As of Aug 05, 2026, Geron (GERN) is trading at a price of 1.3400 USD, with a previous close of 1.2800 USD. The stock has fluctuated within a day range of 1.3100 USD to 1.3600 USD, while its 52-week range spans from 1.0400 USD to 2.0100 USD.
What Is Geron (GERN) Price Target According to Analysts?
The average 12-month price target for Geron is 4.2500 USD, with a high estimate of 6 USD and a low estimate of 3 USD. 4 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +217.16% Upside potential.
What Is the GERN Premarket Price?
GERN's last pre-market stock price is 1.3100 USD. The pre-market share volume is 22,570.0000, and the stock has decreased by 0.0300, or 2.3400%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.